Skip directly to site content

Panel:   Cefiderocol Verification (FDC) (Custom)
AR Bank # 0274 Acinetobacter baumannii
Study ID: ACI-02

Biosample Accession #: SAMN04901664

   
MLST: ST2(Pasteur), ST208(Oxford)

This panels contains isolates from other AR Bank collections/panels.

MICs obtained by broth microdilution. Modal MIC is reported.

MIC results for each antimicrobial agent for an isolate may commonly be ± 1 log2 (doubling dilution) different than what is posted on the FDA & CDC AR Bank website because this is the normal technical variability of antimicrobial susceptibility testing (see J. H. Jorgensen. 1993. J Clin Microbiol. Vol 31[11]: 2841-2844).

Panel:  Acinetobacter baumannii (ACI)  |  Cefiderocol Verification (FDC) (Custom)


MIC (μg/ml) Results and Interpretation
Drug MIC (μg/ml) INT
Amikacin 16S
Ampicillin/sulbactam 1>32R
Cefepime 32R
Cefiderocol 0.12S
Cefotaxime >64R
Ceftazidime 64R
Ceftriaxone >32R
Ciprofloxacin >8R
Colistin 41I
Doripenem >8R
Gentamicin >16R
Imipenem >64R
Imipenem/relebactam 1 2>16R
Imipenem+chelators 3>32---
Levofloxacin >8R
Meropenem >8R
Minocycline 16R
Piperacillin/tazobactam 1>128R
Tetracycline >32R
Tigecycline 21---
Tobramycin 8I
Trimethoprim/sulfamethoxazole 1>8R
MICs obtained by broth microdilution. Modal MIC is reported
S – I –R Interpretation (INT) derived from CLSI 2023 M100 S33

1 Reflects MIC of first component
2 Based on FDA break points
3 Screen for metallo-beta-lactamase production [Rasheed et al. Emerging Infectious Diseases. 2013. 19(6):870-878]
4 Clinical and PK/PD data demonstrate colistin has limited clinical efficacy, even if an intermediate result is obtained. Alternative agents are strongly preferred. Colistin should be used in combination with one or more active antimicrobial agents. Consultation with an infectious disease specialist is recommended.
Molecular Mechanisms of Resistance
CategoryGene
Aminoglycoside aac(3)-Ia, aadA1, aph(3')-Ia, aph(6)-Id, strA
Beta-lactam ADC-30, OXA-66, OXA-72, TEM-1D
Efflux pumps/Other ADEC, qacEdelta1
Fosfomycin ABAF
Sulfonamides sul1, sul2
Tetracyclines tet(B)
 
Disclaimer:
The resistance mechanisms listed were identified by analysis of whole genome sequence using the ResFinder database (last updated June 2, 2016 and accessed on October 25, 2016). This analysis does not include mutations that may result in antibiotic resistance or resistance determinants added to newer versions of the ResFinder database or other antimicrobial resistance gene databases. Biosample accession numbers have been provided so that users can analyze the data on their own if so desired.
Propagation
MEDIUM
Medium: Trypticase Soy Agar with 5% Sheep Blood (BAP)

GROWTH CONDITIONS
Temperature: 35°C
Atmosphere: Aerobic

PROPAGATION PROCEDURE

Remove the sample vial to a container with dry ice or a freezer block. Keep vial on ice or block. (Do not let vial content thaw)

Open vial aseptically to avoid contamination

Using a sterile loop, remove a small amount of frozen isolate from the top of the vial

Aseptically transfer the loop to BAP

Use streak plate method to isolate single colonies

Incubate inverted plate at 35°C ± 2 °C for 20-24 hrs.

Storage Temperature & Biosafety
STORAGE TEMPERATURE: -70°C

BIOSAFETY LEVEL: 2
Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the current publication of 'BioSafety in Microbiological and Biomedical Laboratories' from the U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, and National Institutes of Health.

Disclaimer:
This product is sent with the condition that you are responsible for its safe storage, handling, and use. All materials are the property of the Centers for Disease Control and Prevention (CDC) and have been made available on behalf of the Food and Drug Administration (FDA). This material is not for use in human subjects and may not be redistributed. While CDC uses reasonable efforts to include accurate and up-to-date information on this product sheet, CDC makes no warranties or representations as to its accuracy. CDC is not liable for damages arising from the misidentification or misrepresentation of cultures. Please refer to the Standard Letter Agreement (SLA) for further details regarding the use of this product.
Isolate History
Date Action Performed
05/02/23Gene was added: qacEdelta1
05/02/23Gene was added: ADEC
05/02/23Gene was added: tet(B)
05/02/23Gene was added: ABAF
05/02/23Gene was added: aph(6)-Id
05/02/23Category was added: Efflux pumps/Other
05/02/23Category was added: Tetracyclines
05/02/23Category was added: Fosfomycin
05/02/23Gene was added: ADC-30
05/02/23Gene was added: aph(3')-Ia
05/02/23Gene was added: aadA1
05/02/23Gene was removed: ADC-25
05/02/23Gene was removed: strB
05/02/23Gene was removed: aph(3')-Ic
05/02/23MLST was updated: from --- to ST208(Oxford)
05/02/23MLST was updated: from --- to ST2(Pasteur)
08/11/22Interpretation was updated with a new value for Tobramycin: from S to I
08/11/22Interpretation was updated with a new value for Minocycline: from I to R
08/11/22MIC was updated with a new value for Tobramycin: from 4 to 8
08/11/22MIC was updated with a new value for Minocycline: from 8 to 16
Top of Page
TOP